Moors & Cabot’s CRISPR Therapeutics CRSP Stock Holding History

Moors & Cabot’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$408K	Buy	7,373 +641	+10%	+$34.6K	0.02%	639
2026 Q2	$367K	Buy	6,732 +1,775	+36%	+$93.6K	0.01%	667
2026 Q1	$236K	Sell	4,957 -90	-2%	-$4.75K	0.01%	805
2025 Q4	$265K	Sell	5,047 -108	-2%	-$6.47K	0.01%	737
2025 Q3	$334K	Sell	5,155 -300	-5%	-$17.2K	0.01%	636
2025 Q2	$265K	Buy	+5,455	New	+$211K	0.01%	696
2024 Q2	–	Sell	-2,963	Closed	-$202K	–	881
2024 Q1	$202K	Sell	2,963 -620	-17%	-$44.4K	0.01%	813
2023 Q4	$224K	Buy	+3,583	New	+$198K	0.01%	715
2021 Q4	–	Sell	-2,035	Closed	-$228K	–	913
2021 Q3	$228K	Buy	2,035 +150	+8%	+$18.8K	0.01%	704
2021 Q2	$305K	Buy	1,885 +145	+8%	+$17.6K	0.02%	561
2021 Q1	$212K	Buy	+1,740	New	+$263K	0.02%	663

Other funds holding CRSP

GSK plc London $497M AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Moors & Cabot's CRSP Position: Q3 2026 in Review

Moors & Cabot increased its CRISPR Therapeutics (CRSP) stake by 9.5% in Q3 2026, buying an estimated $34.6K and bringing the position to 7,373 shares worth $408K. The position accounts for 0.02% of the portfolio, ranked #639.

Moors & Cabot first reported a position in CRSP in Q1 2021 and has held it in 11 quarters since. 236 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

Moors & Cabot held 7,373 shares of CRISPR Therapeutics worth $408K as of Q3 2026.
Moors & Cabot bought 641 CRISPR Therapeutics shares in Q3 2026, an estimated $34.6K.
CRISPR Therapeutics made up 0.02% of Moors & Cabot's portfolio in Q3 2026, its #639 holding.
Moors & Cabot first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 11 quarters since.
236 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Moors & Cabot's 13F filing for Q3 2026, filed 6 Nov 2026.